Northwestern Medicine names breast cancer OncoSET program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NORTHWESTERN MEDICINE and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University officially named the Lynn Sage Cancer Research Foundation Breast Cancer OncoSET program.

LSCRF Breast Cancer OncoSET will combine oncology with genomic tumor profiling. The program will initially focus on patients with breast cancer that is non-responsive to traditional therapeutic treatments, and will serve as an extension of the Northwestern OncoSET program that was first launched earlier this year by the Lurie Cancer Center, in collaboration with Northwestern Memorial Hospital.

The Breast Cancer OncoSET program was made possible by a generous donation from the Lynn Sage Cancer Research Foundation, which is the first major naming gift that a Northwestern OncoSET program has received.

YOU MAY BE INTERESTED IN

Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
FDA has granted an accelerated approval to RP1 (vusolimogene oderparepvec) following the agency’s Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login